Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 7/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882026 | 0.81 | MAOB (0.50) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10263726 | 0.81 | CYP11B1 (0.58) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9602018 | 0.80 | NPC1 (0.61) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22540450 | 0.79 | IDO1 (0.51) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL146559 | 0.79 | NPC1 (0.65) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31716043 | 0.79 | WNT3A (0.60) | CYP11B1HPGDSWNT3ACYP11B2SMN1; SMN2 | |
| SCHEMBL8174949 | 0.79 | RAB9A (0.58) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15304189 | 0.78 | KDM1A (0.54) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL328396 | 0.78 | HPGDS (0.56) | CYP11B1HPGDSWNT3ANPC1RAB9A | |
| SCHEMBL31716601 | 0.78 | WNT3A (0.59) | CYP11B1HPGDSWNT3ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | CYP11B1 4031/4885HPGDS 3557/4885WNT3A 4704/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | CYP11B1 1944/4885HPGDS 1604/4885WNT3A 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.